Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

IMPORTANCE: Tumor mutational burden (TMB), as measured by whole-exome sequencing (WES) or a cancer gene panel (CGP), is associated with immunotherapy responses. However, whether TMB estimated by circulating tumor DNA in blood (bTMB) is associated with clinical outcomes of immunotherapy remains to be...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Wang, Zhijie, Duan, Jianchun, Cai, Shangli, Han, Miao, Dong, Hua, Zhao, Jun, Zhu, Bo, Wang, Shuhang, Zhuo, Minglei, Sun, Jianguo, Wang, Qiming, Bai, Hua, Han, Jiefei, Tian, Yanhua, Lu, Jing, Xu, Tongfu, Zhao, Xiaochen, Wang, Guoqiang, Cao, Xinkai, Li, Fugen, Wang, Dalei, Chen, Yuejun, Bai, Yuezong, Zhao, Jing, Zhao, Zhengyi, Zhang, Yuzi, Xiong, Lei, He, Jie, Gao, Shugeng, Wang, Jie
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2019
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512308/
https://ncbi.nlm.nih.gov/pubmed/30816954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.7098
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items